The Movement is on! Join us in advancing cannabis science to elevate the industry
By Pelin Thorogood, Co-founder and Executive Chair of Radicle Science & Nicole Brown, Chief Innovation Officer of Open Book Extracts
Millions of CBD consumers are asking for scientifically-validated information about the products they use, and Radicle Science and Open Book Extracts (OBX) are aligning to answer the call. Our newly announced alliance will redefine how new CBD and cannabinoid products are developed, ensuring the process is backed by large scale, comprehensive, and rigorous consumer use data.
Chief Innovation Officer, OBX
Co-founder & Exec Chair, Radicle Science
Radicle Science + OBX is charting the frontier of a reimagined future.
These efforts also serve as a response to an urgent call from the regulatory bodies, as “the FDA recognizes the significant public interest in cannabis and cannabis-derived compounds, particularly CBD. However, there are many unanswered questions about the science, safety, and quality of products containing CBD.”
The natural products industry and consumers alike are eager for evidence-based health data, and we’re seeing this factor most prominently in the CBD and cannabis space. We’re energized by this burgeoning movement to democratize scientific insights about natural products, which will, we firmly believe, lead to healthier lives.
Radicle Science + OBX is charting the frontier of a reimagined future. When we collectively push in the same direction, all of us – consumers, retailers, patients and even physicians – will soon be able to make more informed decisions about natural products. We are merely among the first movers in a much larger movement. This is so much bigger than us.
By aligning the medical, scientific and technological expertise of Radicle Science with the deep understanding of cannabinoid ingredients, formulations, delivery systems, and production innovation of OBX, our learning curve will be swift. With typical clinical trials, their high recruitment costs limit study sizes, resulting in data collection from small and often homogeneous populations.
Our virtual, direct-to-consumer approach enables large-scale studies that are inclusive of heterogeneous populations with varying demographics, behaviors, and pre-existing conditions, allowing us to compare the effectiveness of different formulas and dosages across diverse population segments. Additionally, instead of the typical multi-year duration for a clinical trial to reach completion, our proprietary platform enables trials to be completed in under six months at a fraction of the cost.
In essence, the high speed, low cost and large scale of our studies enable a significant breakthrough that paves the way to personalized use of natural products.
Consumers deserve to be empowered with credible, scientific information to make informed choices about their health.
The CBD trust gap is one of the biggest barriers preventing the CBD and natural products industry from achieving its full potential.
As recently shared by the Consumer Brand Association (CBA), “A July 2021 Consumer Brands/Ipsos poll of 1,000 American adults found that Americans rated their knowledge of CBD as a 3.3 on a scale of 1 to 10.”
We can bridge that gap. Consumers deserve to be empowered with credible, scientific information to make informed choices about their health. Our rigorous studies into specific formulations of high-quality CBD and minor cannabinoids will reveal far richer data than ever before to inform a new gold standard for product development that is targeted, trusted, and inclusive. Together, we will completely shift how CBD is perceived, powering a movement the industry has not seen to date.
We are inviting CBD and other cannabinoid product brands to join in this movement. Reach out here to learn how to get involved. What we can accomplish together will be nothing short of transformative and has the power to completely redefine the industry.